|
Proportion of patients with HIV-1 RNA <400 copies/mL and <50 copies/mL |
|||||||||||
| Week |
HIV-1 RNA <400 copies/mL, n/N (%) |
HIV-1 RNA <50 copies/mL, n/N (%) |
|||||||||
|
|
|||||||||||
| ITT: Observed |
ITT: M = F |
ITT: Observed |
ITT: M = F |
||||||||
| Abacavir |
PI |
Abacavir |
PI |
Abacavir |
PI |
Abacavir |
PI |
||||
|
|
|||||||||||
| Baseline |
52/52 (100) |
52/52 (100) |
52/52 (100) |
52/52 (100) |
42/52 (81) |
47/52 (90) |
42/52 (81) |
47/52 (90) |
|||
| 4 |
49/49 (100) |
44/45 (98) |
49/52 (94) |
44/52 (85) |
48/49 (98) |
43/45 (96) |
48/52 (92) |
43/52 (83) |
|||
| 8 |
39/42 (93) |
42/42 (100) |
39/52 (75) |
42/52 (81) |
38/42 (90) |
40/42 (95) |
38/52 (73) |
40/52 (77) |
|||
| 12 |
38/41 (93) |
40/40 (100) |
38/52 (73) |
40/52 (77) |
38/41 (93) |
39/40 (98) |
38/52 (73) |
39/52 (75) |
|||
| 20 |
38/41 (93) |
40/40 (100) |
38/52 (73) |
40/52 (77) |
32/41 (78) |
38/40 (95) |
32/52 (62) |
38/52 (73) |
|||
| 28 |
36/40 (90) |
40/40 (100) |
36/52 (69) |
40/52 (77) |
32/40 (80) |
39/40 (98) |
32/52 (62) |
39/52 (75) |
|||
|
Abbreviations: ITT = intent to treat; M = F = missing equals failure analysis; PI = protease inhibitor. | |||||||||||
Keiser et al. BMC Infectious Diseases 2005 5:2 doi:10.1186/1471-2334-5-2 |
|||||||||||